
## THE CLINICAL IMPACT OF Casirivimab—Imdevimab Monoclonal Antibody Therapy (CIMAT) IN COVID-19 PATIENTS: A REAL-WORLD INSIGHT FROM INDIA.



1157

Jose J Kochuparambil \*, Aleena Issac



## CONCLUSION

Patients treated with CIMAT for COVID-19 were more clinically benefitted than those treated without the antibody cocktail.

Connect **ME** 

Lets make the ID Week 2022 a great platform to connect

